Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at

Vaccine and Treatment Evaluation Units (VTEUs)

The Vaccine and Treatment Evaluation Units (VTEUs) have played a key role in NIAID’s effort to develop new and improved vaccines and therapies against infectious diseases for over four decades. They have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure. An important strength of the VTEUs is their ability to enroll large numbers of volunteers into trials rapidly and vaccinate them in a safe, effective and quick manner. This rapid-response capability is especially important for testing vaccines designed to counteract emerging public health concerns.

Main Areas of Focus

  • Rapid-response capability
  • Testing novel vaccines
  • Developing combination vaccines
  • Testing novel delivery systems
  • Strengthening the nation's biodefense
Program Overview

NIAID established the Vaccine and Treatment Evaluation Units (VTEUs) in 1962. They provide a ready resource for conducting clinical trials of vaccines and treatments for infectious diseases.


There are nine current VTEU contract award sites.

Content last reviewed on November 17, 2017